EAM
COGT icon

Exome Asset Management’s Cogent Biosciences COGT Stock Holding History

Exome Asset Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-45,000
Closed -$646K – 68
2025
Q3 		$646K Buy
+45,000
New +$533K 0.39% 56

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Exome Asset Management's COGT Position: Q2 2026 in Review

Exome Asset Management reduced its Cogent Biosciences (COGT) stake by 24% in Q2 2026, selling an estimated $2.38M and leaving 210,523 shares worth $8.15M. The position accounts for 5.03% of the portfolio, ranked #4.

Exome Asset Management first reported a position in COGT in Q1 2025 and has held it in 6 quarters since. The position peaked at $10.9M in Q4 2025. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Exome Asset Management held 210,523 shares of Cogent Biosciences worth $8.15M as of Q2 2026.
  • Exome Asset Management sold 68,010 Cogent Biosciences shares in Q2 2026, an estimated $2.38M.
  • Cogent Biosciences made up 5.03% of Exome Asset Management's portfolio in Q2 2026, its #4 holding.
  • Exome Asset Management first reported a position in Cogent Biosciences in Q1 2025 and has held it in 6 quarters since.
  • Exome Asset Management's Cogent Biosciences position peaked at $10.9M in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.